Clinical evidence suggests that antibodies from reconvalescent donors (persons who have recovered from infection) may be effective in the treatment of Ebola virus infection. Administration of this treatment to Ebola virus–infected patients while preventing the transmission of other pathogenic viruses may be best accomplished by use of virus-inactivated reconvalescent plasma
(See the Editorial Commentary by Schooley on pages 503–5.) Background. The current West Africa Ebola...
The COVID-19 pandemic is an emerging new human disease, for which no vaccines, or monoclonal antibod...
Vaccination is one of our most powerful antiviral strategies. Despite the emergence of deadly viruse...
Background Ebola virus (EBOV) neutralizing antibody in plasma may reduce viral load following admini...
Background Better treatments are urgently needed for the management of Ebola virus epidemics in Equa...
Background: Better treatments are urgently needed for the management of Ebola virus epidemics in Equ...
The survival of 7 of 8 patients with Ebola virus (EBOV) infection after transfusions of convalescent...
International audienceIn the wake of the recent outbreak of Ebola virus disease (EVD) in several Afr...
BACKGROUND: Passive therapy with convalescent plasma provides an early opportunity to intervene in E...
Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnorm...
Ebola virus (EBOV), a member of order Mononegavirales is most famous for causing the endemics of hem...
Convalescent plasma is plasma that is already present in the body and includes anti-SARS-CoV-2 antib...
Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnorm...
The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola Virus Disease (EVD) i...
(See the Editorial Commentary by Schooley on pages 503–5.) Background. The current West Africa Ebola...
The COVID-19 pandemic is an emerging new human disease, for which no vaccines, or monoclonal antibod...
Vaccination is one of our most powerful antiviral strategies. Despite the emergence of deadly viruse...
Background Ebola virus (EBOV) neutralizing antibody in plasma may reduce viral load following admini...
Background Better treatments are urgently needed for the management of Ebola virus epidemics in Equa...
Background: Better treatments are urgently needed for the management of Ebola virus epidemics in Equ...
The survival of 7 of 8 patients with Ebola virus (EBOV) infection after transfusions of convalescent...
International audienceIn the wake of the recent outbreak of Ebola virus disease (EVD) in several Afr...
BACKGROUND: Passive therapy with convalescent plasma provides an early opportunity to intervene in E...
Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnorm...
Ebola virus (EBOV), a member of order Mononegavirales is most famous for causing the endemics of hem...
Convalescent plasma is plasma that is already present in the body and includes anti-SARS-CoV-2 antib...
Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnorm...
The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola Virus Disease (EVD) i...
(See the Editorial Commentary by Schooley on pages 503–5.) Background. The current West Africa Ebola...
The COVID-19 pandemic is an emerging new human disease, for which no vaccines, or monoclonal antibod...
Vaccination is one of our most powerful antiviral strategies. Despite the emergence of deadly viruse...